{"id":"https://openalex.org/W1996693517","doi":"https://doi.org/10.1002/(sici)1099-081x(199601)17:1<43::aid-bdd935>3.0.co;2-f","title":"THE RELATIVE BIOAVAILABILITY OF TWO MARKETED CONTROLLED RELEASE DILTIAZEM DOSAGE FORMS AT STEADY STATE IN HEALTHY VOLUNTEERS","display_name":"THE RELATIVE BIOAVAILABILITY OF TWO MARKETED CONTROLLED RELEASE DILTIAZEM DOSAGE FORMS AT STEADY STATE IN HEALTHY VOLUNTEERS","publication_year":1996,"publication_date":"1996-01-01","ids":{"openalex":"https://openalex.org/W1996693517","doi":"https://doi.org/10.1002/(sici)1099-081x(199601)17:1<43::aid-bdd935>3.0.co;2-f","mag":"1996693517","pmid":"https://pubmed.ncbi.nlm.nih.gov/8991490"},"language":"en","primary_location":{"id":"doi:10.1002/(sici)1099-081x(199601)17:1<43::aid-bdd935>3.0.co;2-f","doi":"https://doi.org/10.1002/(sici)1099-081x(199601)17:1<43::aid-bdd935>3.0.co;2-f","is_oa":false,"landing_page_url":"https://doi.org/10.1002/(sici)1099-081x(199601)17:1<43::aid-bdd935>3.0.co;2-f","pdf_url":null,"source":{"id":"https://openalex.org/S57691945","display_name":"Biopharmaceutics & Drug Disposition","issn_l":"0142-2782","issn":["0142-2782","1099-081X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biopharmaceutics &amp; Drug Disposition","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077567676","display_name":"Christina L. Lippert","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"C. L. LIPPERT","raw_affiliation_strings":["Marion Merrell Dow Inc., Kansas City, MO 64134-0627, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marion Merrell Dow Inc., Kansas City, MO 64134-0627, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061464180","display_name":"Thangam Arumugham","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. ARUMUGHAM","raw_affiliation_strings":["Marion Merrell Dow Inc., P.O. Box 9627, Kansas City, MO, 64134-0627, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marion Merrell Dow Inc., P.O. Box 9627, Kansas City, MO, 64134-0627, U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023954017","display_name":"Vijay O. Bhargava","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. O. BHARGAVA","raw_affiliation_strings":["Marion Merrell Dow Inc., Kansas City, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marion Merrell Dow Inc., Kansas City, U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060543579","display_name":"Mark G. Eller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. ELLER","raw_affiliation_strings":["Marion Merrell Dow Inc., Kansas City, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marion Merrell Dow Inc., Kansas City, U.S.A","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5002299630","display_name":"Scott James Weir","orcid":"https://orcid.org/0000-0002-8020-434X","observed_orcids":["https://orcid.org/0000-0002-8020-434X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. J. WEIR","raw_affiliation_strings":["Marion Merrell Dow Inc., Kansas City, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marion Merrell Dow Inc., Kansas City, U.S.A","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5077567676"],"corresponding_institution_ids":[],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":null,"fwci":0.4134,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.52888752,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"17","issue":"1","first_page":"43","last_page":"54"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.3882000148296356,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.3882000148296356,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.13230000436306,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.13040000200271606,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/diltiazem","display_name":"diltiazem","score":0.9990000128746033},{"id":"https://openalex.org/keywords/relative-bioavailability","display_name":"relative bioavailability","score":0.8149999976158142},{"id":"https://openalex.org/keywords/bioequivalence","display_name":"bioequivalence","score":0.9610000252723694},{"id":"https://openalex.org/keywords/controlled-release-formulation","display_name":"controlled-release formulation","score":0.7269999980926514},{"id":"https://openalex.org/keywords/steady-state-pharmacokinetics","display_name":"steady-state pharmacokinetics","score":0.7960000038146973},{"id":"https://openalex.org/keywords/plasma-concentration-time-curve","display_name":"plasma concentration-time curve","score":0.6290000081062317},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.5149999856948853},{"id":"https://openalex.org/keywords/inter-individual-variability","display_name":"interindividual variability","score":0.6959999799728394}],"concepts":[{"id":"https://openalex.org/C2778335254","wikidata":"https://www.wikidata.org/wiki/Q5137314","display_name":"Cmin","level":4,"score":0.9121788144111633},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.9066932201385498},{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.8676139116287231},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8420951962471008},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.8113415241241455},{"id":"https://openalex.org/C8171440","wikidata":"https://www.wikidata.org/wiki/Q903414","display_name":"Steady state (chemistry)","level":2,"score":0.6191200613975525},{"id":"https://openalex.org/C2776741139","wikidata":"https://www.wikidata.org/wiki/Q422229","display_name":"Diltiazem","level":3,"score":0.5988028049468994},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5967583656311035},{"id":"https://openalex.org/C2910800852","wikidata":"https://www.wikidata.org/wiki/Q7846541","display_name":"Trough Concentration","level":3,"score":0.49157270789146423},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.48664650321006775},{"id":"https://openalex.org/C2776768635","wikidata":"https://www.wikidata.org/wiki/Q3427301","display_name":"Volunteer","level":2,"score":0.42556536197662354},{"id":"https://openalex.org/C140793950","wikidata":"https://www.wikidata.org/wiki/Q168091","display_name":"Animal science","level":1,"score":0.33557409048080444},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.24996042251586914},{"id":"https://openalex.org/C519063684","wikidata":"https://www.wikidata.org/wiki/Q706","display_name":"Calcium","level":2,"score":0.08970916271209717},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.061009883880615234},{"id":"https://openalex.org/C6557445","wikidata":"https://www.wikidata.org/wiki/Q173113","display_name":"Agronomy","level":1,"score":0.0},{"id":"https://openalex.org/C147789679","wikidata":"https://www.wikidata.org/wiki/Q11372","display_name":"Physical chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004110","descriptor_name":"Diltiazem","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004110","descriptor_name":"Diltiazem","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D004110","descriptor_name":"Diltiazem","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/(sici)1099-081x(199601)17:1<43::aid-bdd935>3.0.co;2-f","doi":"https://doi.org/10.1002/(sici)1099-081x(199601)17:1<43::aid-bdd935>3.0.co;2-f","is_oa":false,"landing_page_url":"https://doi.org/10.1002/(sici)1099-081x(199601)17:1<43::aid-bdd935>3.0.co;2-f","pdf_url":null,"source":{"id":"https://openalex.org/S57691945","display_name":"Biopharmaceutics & Drug Disposition","issn_l":"0142-2782","issn":["0142-2782","1099-081X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biopharmaceutics &amp; Drug Disposition","raw_type":"journal-article"},{"id":"pmid:8991490","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8991490","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biopharmaceutics & drug disposition","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2062741616","https://openalex.org/W2004078823","https://openalex.org/W2078473877","https://openalex.org/W2367142317","https://openalex.org/W2371395769","https://openalex.org/W2400287785","https://openalex.org/W2147067030","https://openalex.org/W177921628","https://openalex.org/W2096997559","https://openalex.org/W2387773086"],"abstract_inverted_index":{"This":[0],"study":[1],"was":[2,116],"conducted":[3],"to":[4,14,103,124,137,148,163],"determine":[5],"the":[6,44,70,109,112,125,140],"relative":[7],"bioavailability":[8],"of":[9,56,66,170],"Dilacor":[10,57,83,113,132,158],"XR":[11,58,84,114,133,159],"capsules":[12,17],"compared":[13,123],"Cardizem":[15,67,95,126,143,164],"CD":[16,68,96,127,144,165],"at":[18,166],"both":[19],"low":[20],"(180":[21],"mg":[22,27,72,76,172,176],"d-1)":[23,28],"and":[24,32,38,61,74,91,174],"high":[25],"(540":[26],"dose":[29,78],"levels.":[30],"Trough":[31],"serial":[33],"plasma":[34,52],"samples":[35],"were":[36,41,59],"obtained":[37],"pharmacokinetic":[39,121],"parameters":[40],"calculated":[42,120],"from":[43,101,111,135,146],"steady":[45,50,167],"state":[46,51,168],"concentration-time":[47],"profiles.":[48],"Mean":[49],"diltiazem":[53],"concentrations":[54],"(AUCss(0-24))":[55],"19%":[60],"26%":[62],"lower":[63,86],"than":[64,94],"those":[65],"for":[69,118,131,142],"180":[71,171],"d-1":[73,77,173],"540":[75,175],"levels,":[79],"respectively.":[80],"In":[81],"addition,":[82],"had":[85],"mean":[87],"Cmax,ss,":[88],"Tmax,ss,":[89],"Cmin,ss,":[90],"trough":[92],"values":[93],"with":[97],"percentage":[98],"differences":[99],"ranging":[100],"17%":[102],"29%.":[104],"The":[105,129],"variability":[106],"(%CV)":[107],"in":[108],"data":[110],"treatments":[115],"higher":[117],"each":[119],"parameter":[122],"treatments.":[128],"%CV":[130,141],"ranged":[134,145],"34%":[136],"104%":[138],"while":[139],"21%":[147],"49%.":[149],"From":[150],"these":[151],"results,":[152],"it":[153],"may":[154],"be":[155],"concluded":[156],"that":[157],"is":[160],"not":[161],"bioequivalent":[162],"doses":[169],"d-1.":[177]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}